92830-99-4

Basic information

• Product Name: 3(2H)-Benzofuranone, 2-[(4-fluorophenyl)methylene]-
• CAS NO: 92830-99-4
• Molecular Formula: C15H9FO2
• Molecular Weight: 240.234
• Mol File: 92830-99-4.mol
• Article Data: 14

Chemical Properties

• CAS DataBase Reference: 3(2H)-Benzofuranone, 2-[(4-fluorophenyl)methylene]-(CAS DataBase Reference)
• NIST Chemistry Reference: 3(2H)-Benzofuranone, 2-[(4-fluorophenyl)methylene]-(92830-99-4)
• EPA Substance Registry System: 3(2H)-Benzofuranone, 2-[(4-fluorophenyl)methylene]-(92830-99-4)

Safety Data

• Hazardous Substances Data: 92830-99-4(Hazardous Substances Data)

Upstream product

• 7169-34-8 3-oxo-2,3-dihydrobenzo[b]furan 
• 459-57-4 4-fluorobenzaldehyde 
• 92830-84-7 4-fluoro-2'-hydroxychalcone dibromide 
• 1840-01-3 (E)-1-(2-hydroxyphenyl)-3-(4-fluorophenyl)prop-2-en-1-one 
• 108-95-2 phenol 
• 122-59-8 2-phenoxyacetic acid 
• 1607814-80-1 2-[3-(4-fluorophenyl)propynoyl]phenol 
• 1840-01-3 3-(4-fluorophenyl)-1-(2-hydroxyphenyl)prop-2-en-1-one 
• 118-93-4 o-hydroxyacetophenone 
• 766-98-3 1-ethynyl-4-fluorobenzene 
• 64-18-6 formic acid 
• 533-58-4 2-Iodophenol 
• 201230-82-2 carbon monoxide 

Downstream Products

• 82158-22-3 p-fluorophenyl(benzofuran-2-yl)methanol 
• 27044-77-5 benzofuran-2-yl(4-fluorophenyl)methanone 

Relevant articles and documents

6-Hydroxy-benzofuran-3-(2H)-ones as Potential Anti-Inflammatory Agents: Synthesis and Inhibitory Activity of LPS-Stimulated ROS Production in RAW 264.7 Macrophage

-

Diversity-oriented synthesis of benzofuro[3,2-b]pyridine derivatives from aurone-derived α,β-unsaturated imines and activated terminal alkynes

An efficient annulation reaction of aurone-derived α,β-unsaturated imines and activated terminal alkynes mediated by triethylamine is described, which enables the facile synthesis of 1,4-dihydrobenzofuro[3,2-b]pyridines in high yields. When the nucleophil

Discovery of benzofuran-3(2H)-one derivatives as novel DRAK2 inhibitors that protect islet β-cells from apoptosis

Death-associated protein kinase-related apoptosis-inducing kinase-2 (DRAK2) is a serine/threonine kinase that plays a key role in a wide variety of cell death signaling pathways. Inhibition of DRAK2 was found to efficiently protect islet β-cells from apoptosis and hence DRAK2 inhibitors represent a promising therapeutic strategy for the treatment of diabetes. Only very few chemical entities targeting DRAK2 are currently known. We carried out a high throughput screening and identified compound 4 as a moderate DRAK2 inhibitor with an IC50value of 3.15?μM. Subsequent SAR studies of hit compound 4 led to the development of novel benzofuran-3(2H)-one series of DRAK2 inhibitors with improved potency and favorable selectivity profiles against 26 selected kinases. Importantly, most potent compounds 40 (IC50?=?0.33?μM) and 41 (IC50?=?0.25?μM) were found to protect islet β-cells from apoptosis in dose-dependent manners. These data support the notion that small molecule inhibitors of DRAK2 represents a promising strategy for the treatment of diabetes.